3,091 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Eagle Strategies LLC

Eagle Strategies LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 3,091 shares of the biopharmaceutical company's stock, valued at approximately $286,000.

Several other large investors have also made changes to their positions in the company. Pine Valley Investments Ltd Liability Co bought a new stake in Gilead Sciences in the third quarter valued at approximately $209,000. World Investment Advisors LLC increased its stake in Gilead Sciences by 33.6% in the 3rd quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock valued at $2,180,000 after buying an additional 6,535 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its stake in shares of Gilead Sciences by 278.4% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 18,660 shares of the biopharmaceutical company's stock worth $1,564,000 after buying an additional 13,729 shares during the last quarter. Tidal Investments LLC increased its position in shares of Gilead Sciences by 9.9% in the third quarter. Tidal Investments LLC now owns 111,464 shares of the biopharmaceutical company's stock valued at $9,345,000 after acquiring an additional 10,078 shares during the last quarter. Finally, Synovus Financial Corp raised its holdings in Gilead Sciences by 99.6% during the third quarter. Synovus Financial Corp now owns 37,265 shares of the biopharmaceutical company's stock worth $3,124,000 after acquiring an additional 18,592 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Performance

NASDAQ GILD traded up $1.16 during trading on Wednesday, hitting $99.04. 2,873,354 shares of the company's stock traded hands, compared to its average volume of 7,518,522. The stock has a market capitalization of $123.32 billion, a price-to-earnings ratio of 267.97, a PEG ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The business has a 50 day moving average of $108.26 and a 200-day moving average of $99.09. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the company earned ($1.32) earnings per share. The business's revenue for the quarter was down .3% on a year-over-year basis. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 3.19%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is presently 66.53%.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at $17,597,559.49. This trade represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 160,605 shares of company stock worth $16,718,136 over the last ninety days. Company insiders own 0.27% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GILD. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Oppenheimer decreased their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Finally, Royal Bank of Canada boosted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research report on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.